{"url_path":"/sec/bcyc/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1761612/0001104659-26-065231-index.html","accession_number":"0001104659-26-065231","cik":"0001761612","ticker":"BCYC","issuer_name":"BICYCLE THERAPEUTICS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1761612/0001104659-26-065231-index.html","primary_entity_key":"0001761612","primary_entity_name":"BICYCLE THERAPEUTICS PLC"},"word_count":360,"has_tables":true,"body_markdown":"false\n0001761612\nX0\n00-0000000\ntrue\n\n0001761612\n\n2026-05-21\n2026-05-21\n\n0001761612\n\nus-gaap:CommonStockMember\n\n2026-05-21\n2026-05-21\n\n0001761612\n\nbcyc:AmericanDepositarySharesMember\n\n2026-05-21\n2026-05-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section\n13 or 15(d) of the Securities Exchange Act of 1934**\n\n** **\n\n**May 21, 2026**\n\nDate of Report (Date of earliest event reported)\n\n \n\n**Bicycle\nTherapeutics plc**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**England\nand Wales**\n \n**001-38916**\n \n**Not\napplicable**\n\n(State or other jurisdiction\n\nof incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(IRS Employer\n\nIdentification No.)\n\n \n\n**Blocks\nA & B, Portway Building****, Granta\nPark Great Abington****, Cambridge****United Kingdom**\n\n**CB21\n6GS**\n\n(Address of principal\nexecutive offices)\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area code: **+44****1223 261503**\n\n  \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n  \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n  \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n  \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title\nof each class**\n**Trading\nSymbol (s)**\n**Name\nof each exchange on which registered**\n\nOrdinary\nshares, nominal value £0.01 per share\nn/a\nThe\nNasdaq\nStock Market LLC*\n\nAmerican\nDepositary Shares, each representing one ordinary share, nominal value £0.01 per share\nBCYC\nThe\nNasdaq\nStock Market LLC\n\n** **\n\n*****Not\nfor trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). \n\n \n\nEmerging growth company  ¨\n\n \n\nIf an emerging\ngrowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any\nnew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}